Everest Financial Group LLC Acquires New Position in Merck & Co., Inc. $MRK

Everest Financial Group LLC bought a new position in Merck & Co., Inc. (NYSE:MRK) in the first quarter, Holdings Channel reports. The firm bought 10,475 shares of the company’s stock, valued at approximately $1,260,000.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Merck & Co., Inc. by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company’s stock worth $26,770,014,000 after buying an additional 2,185,853 shares during the last quarter. State Street Corp lifted its stake in shares of Merck & Co., Inc. by 1.6% during the fourth quarter. State Street Corp now owns 120,040,168 shares of the company’s stock worth $12,737,504,000 after buying an additional 1,859,990 shares during the period. Wellington Management Group LLP grew its holdings in shares of Merck & Co., Inc. by 14.8% during the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock valued at $9,098,196,000 after buying an additional 11,156,354 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Merck & Co., Inc. by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company’s stock valued at $6,307,572,000 after buying an additional 249,110 shares during the last quarter. Finally, Morgan Stanley increased its position in shares of Merck & Co., Inc. by 0.8% in the 4th quarter. Morgan Stanley now owns 44,946,021 shares of the company’s stock valued at $4,731,018,000 after acquiring an additional 359,486 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on MRK. Wells Fargo & Company raised their target price on Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 8th. Wall Street Zen downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Morgan Stanley increased their price objective on Merck & Co., Inc. from $112.00 to $113.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th. Bank of America raised their price objective on Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Finally, Citigroup began coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $133.94.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced initial access plans for alimatravir, its investigational once-monthly oral HIV PrEP in Phase 3 development, and said it has signed voluntary licensing agreements covering 129 countries. That broad access strategy could support adoption in large international markets if the drug is approved. Article Title
• Neutral Sentiment: Merck also issued a company release on the same alimatravir access plan, reinforcing that the program is moving forward and that it is trying to expand availability in regions that account for most new HIV diagnoses globally. Article Title
• Neutral Sentiment: Traders also bought a high volume of Merck call options, which may reflect rising bullish speculation around the stock and the HIV pipeline, but it does not by itself change fundamentals. Article Title
• Negative Sentiment: Par Health launched the first generic version of Janumet XR in the U.S., which may pressure Merck’s diabetes-related sales and adds another competitive headwind for an established product. Article Title

Merck & Co., Inc. Trading Up 0.4%

Shares of Merck & Co., Inc. stock opened at $131.06 on Friday. The stock has a market cap of $323.68 billion, a PE ratio of 36.92, a price-to-earnings-growth ratio of 5.20 and a beta of 0.19. The firm has a fifty day moving average price of $121.67 and a 200 day moving average price of $117.71. Merck & Co., Inc. has a 1 year low of $76.66 and a 1 year high of $131.74. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. The company had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm’s revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the company earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities research analysts predict that Merck & Co., Inc. will post 2.74 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th were issued a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend was Monday, June 15th. Merck & Co., Inc.’s payout ratio is 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.